Pear Therapeutics today touted results from an extended retrospective analysis of real-world data for its reSET-O prescription digital therapeutic. Boston-based Pear Therapeutics developed its reSET-O prescription digital therapeutic (PDT) for … [Read More...] about Pear Therapeutics touts 9-month data for reSET-O
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Medtronic launches Prevail drug-coated balloon catheter in Europe
Medtronic (NYSE:MDT) today announced that it has launched its Prevail drug-coated balloon catheter in Europe. The medtech giant designed the Prevail catheter for percutaneous coronary intervention procedures to treat narrowed or blocked coronary … [Read More...] about Medtronic launches Prevail drug-coated balloon catheter in Europe
Tyme wins U.S. patent for drug delivery method for cancer treatment
Tyme Technologies (NSDQ:TYME) announced today that it received a U.S. patent for its metabolomic drug delivery platform. Bedminster, N.J.-based Tyme's additional patent claims related to the metabolomic technology platform (U.S. Patent No. … [Read More...] about Tyme wins U.S. patent for drug delivery method for cancer treatment
Innovative Health Sciences wins CE mark for syringe infusion system
Innovative Health Sciences announced today that it received CE mark approval in Europe for its Insignis syringe infusion system. Chester, N.Y.–based Innovative Health Sciences designed the Insignis syringe infusion system to offer a combination of … [Read More...] about Innovative Health Sciences wins CE mark for syringe infusion system
American Lung Association slams cigarette maker for inhaled medical therapy acquisition
The American Lung Association condemned the recently announced acquisition of Vectura by cigarette maker Philip Morris (NYSE:PM). Earlier this month, Philip Morris announced that it agreed to acquire inhaled drug delivery technology … [Read More...] about American Lung Association slams cigarette maker for inhaled medical therapy acquisition
Xeris, Tetra Pharma enter $71M licensing agreement for glucagon injection
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo. Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, … [Read More...] about Xeris, Tetra Pharma enter $71M licensing agreement for glucagon injection
FDA approves Nevro spinal cord stimulation to treat chronic pain with diabetic neuropathy
Nevro (NYSE:NVRO) announced today that it received FDA approval for its Senza system for treating chronic pain associated with PDN. Redwood City, Calif.-based Nevro’s Senza system’s approval is specific to Nevro’s 10 kHz stimulation, with the … [Read More...] about FDA approves Nevro spinal cord stimulation to treat chronic pain with diabetic neuropathy
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
As we enter what may be the "new normal," Dexcom's CEO bets the company can pave the way in continuous glucose monitoring. Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion. That's the way … [Read More...] about Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
Pfizer agrees to pay $345M in EpiPen pricing lawsuit
Pfizer (NYSE:PFE) agreed to pay $345 million to settle claims of overpayments for EpiPens due to alleged anti-competitive and unfair practices. Reuters reported that a filing disclosed in federal court in Kansas City, Kan., revealed the settlement … [Read More...] about Pfizer agrees to pay $345M in EpiPen pricing lawsuit
FDA clears Dexcom Partner Web APIs
Dexcom (NSDQ:DXCM) announced today that it received FDA clearance for its Dexcom Partner Web application programming interfaces (APIs). The San Diego-based company's Dexcom Partner Web APIs enable invited third-party developers to integrate … [Read More...] about FDA clears Dexcom Partner Web APIs
FDA grants iStar Medical IDE for glaucoma implant pivotal trial
iSTAR Medical announced today that the FDA granted investigational device exemption to start a pivotal trial with its MINIject implant. Wavre, Belgium–based iStar's MINIject minimally invasive implant for glaucoma surgery will be investigated in … [Read More...] about FDA grants iStar Medical IDE for glaucoma implant pivotal trial
In case you missed it
- Pear Therapeutics touts 9-month data for reSET-O
- Eli Lilly acquires glucose-sensing insulin developer Protomer Technologies
- Suono Bio rasies $8.5M in oversubscribed Series A
- Glytec appoints chief medical officer
- BD announces two new directors for diabetes spinoff
- Cigarette maker spending $1.2 billion on company with inhaled medical therapies
- Thermo Fisher expands gene therapy portfolio
- Thermo Fisher Scientific expands corporate leadership team
- Fresenius Kabi launches Simplist fentanyl citrate injection
- DarioHealth touts data for diabetes management platform
- Teva initiates U.S. recall of Topotecan metastatic ovarian cancer injection treatment
- Nominations open for the Leonard Award celebrating 100 years of insulin
- PharmaJet begins enrollment for needle-free COVID-19 vaccine trial
- United Therapeutics touts study results for inhaled Tyvaso treatment
- Giiant Pharma extends seed round with $1.25M
Clinical Trials
Pear Therapeutics touts 9-month data for reSET-O
Pear Therapeutics today touted results from an extended retrospective analysis of real-world data for its reSET-O prescription digital therapeutic. Boston-based Pear Therapeutics developed its reSET-O prescription digital therapeutic (PDT) for treating opioid use disorder (OUD). According to a news release, results from the nine-month real-world data analysis demonstrated a continued long-term reduction in costly healthcare […]
DarioHealth touts data for diabetes management platform
DarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform. New York-based Dario’s research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine. According to a news release, results —presented at the American Diabetes Association (ADA) 81st […]
PharmaJet begins enrollment for needle-free COVID-19 vaccine trial
PharmaJet announced today that it began enrollment for a Phase 1 clinical trial for its needle-free COVID-19 vaccine in Australia. Golden, Colo.-based PharmaJet’s needle-free injection systems will be studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia. According to a news release, PharmaJet’s system was chosen […]
United Therapeutics touts study results for inhaled Tyvaso treatment
United Therapeutics (NSDQ:UTHR) today announced positive results from an analysis of forced vital capacity (FVC) change with its Tyvaso treatment. Research Triangle Park, N.C.–based United Therapeutics developed Tyvaso (treprostinil) as an inhalation solution for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA approved the treatment in April 2020. The posthoc analysis of […]
Medtronic touts trial results for InPen smart insulin pen, extended infusion system
Medtronic (NYSE:MDT) today presented positive study results for its InPen smart insulin pen and its extended-wear infusion set. Fridley, Minn.-based Medtronic touted real-world clinical results comparing glycemic outcomes for 1,736 individuals before and after using the InPen smart insulin pen for 90 days with a continuous glucose monitor (CGM). According to a news release, data […]
